Exelixis Inc. (EXEL)

20.50
NASDAQ : Health Technology
Prev Close 20.50
Day Low/High 0.00 / 0.00
52 Wk Low/High 18.03 / 32.50
Avg Volume 3.68M
Exchange NASDAQ
Shares Outstanding 296.87M
Market Cap 6.21B
EPS 0.50
P/E Ratio 25.41
Div & Yield N.A. (N.A)

Latest News

Two Oncology Stocks I Like Now

Two Oncology Stocks I Like Now

M&A activity should pick up in the biotech space.

Waste Management, Blackstone Group, Xilinx: 'Mad Money' Lightning Round

Waste Management, Blackstone Group, Xilinx: 'Mad Money' Lightning Round

Jim Cramer weighs in on Waste Management, Blackstone Group, Xilinx, Celgene, Nvidia, Exelixis, Moneygram and more.

Trump, Trade and Tariffs: Cramer's 'Mad Money' Recap (Thursday 5/3/18)

Trump, Trade and Tariffs: Cramer's 'Mad Money' Recap (Thursday 5/3/18)

Jim Cramer thinks that, finally, bargain hunters are just saying, "Enough already! It can't be that bad."

Exelixis' Partner Ipsen Announces EMA Validation Of The Application For A New Indication For CABOMETYX® (cabozantinib) For Previously Treated Advanced Hepatocellular Carcinoma

Exelixis' Partner Ipsen Announces EMA Validation Of The Application For A New Indication For CABOMETYX® (cabozantinib) For Previously Treated Advanced Hepatocellular Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen received validation of the application for variation to the CABOMETYX ® (cabozantinib) marketing authorization from the European Medicines...

Exelixis' Partner Ipsen Announces Positive CHMP Opinion For CABOMETYX® (cabozantinib) For Previously Untreated Intermediate- Or Poor-Risk Advanced Renal Cell Carcinoma

Exelixis' Partner Ipsen Announces Positive CHMP Opinion For CABOMETYX® (cabozantinib) For Previously Untreated Intermediate- Or Poor-Risk Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines...

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXU, INOV, IT, KEYW, QCP, QSR, SHEN Downgrades: AMID, DM, EXEL, GDEN, LCUT, OIS, VJET Initiations: IMOS Read on to get TheStreet Quant Ratings' detailed report:

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

Exelixis Submits U.S. Supplemental New Drug Application For CABOMETYX® (Cabozantinib) For Previously Treated Advanced Hepatocellular Carcinoma

Exelixis Submits U.S. Supplemental New Drug Application For CABOMETYX® (Cabozantinib) For Previously Treated Advanced Hepatocellular Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced it has completed the submission of a supplemental New Drug Application (sNDA) to the U.

Exelixis Announces Webcasts Of Investor Conference Presentations In March

Exelixis Announces Webcasts Of Investor Conference Presentations In March

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis Announces Collaborator Daiichi Sankyo's Submission Of Regulatory Filing For Esaxerenone (CS-3150) In Japan

Exelixis Announces Collaborator Daiichi Sankyo's Submission Of Regulatory Filing For Esaxerenone (CS-3150) In Japan

Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Daiichi Sankyo Company, Limited ("Daiichi Sankyo") has submitted its regulatory application for esaxerenone (INN; code name CS-3150) as a treatment for...

Exelixis Announces Fourth Quarter And Full Year 2017 Financial Results And Provides Corporate Update

Exelixis Announces Fourth Quarter And Full Year 2017 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year of 2017 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and...

Exelixis To Present At The RBC Capital Markets Global Healthcare Conference On February 21, 2018

Exelixis To Present At The RBC Capital Markets Global Healthcare Conference On February 21, 2018

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis Announces Results From A Phase 2 Investigator-Sponsored Trial Of Cabozantinib In The First-Line Treatment Of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

Exelixis Announces Results From A Phase 2 Investigator-Sponsored Trial Of Cabozantinib In The First-Line Treatment Of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced results from a phase 2 investigator-sponsored trial (IST) of cabozantinib for the first-line treatment of metastatic radioiodine (RAI)-refractory differentiated thyroid...

Exelixis To Release Fourth Quarter And Full Year 2017 Financial Results On Monday, February 26, 2018

Exelixis To Release Fourth Quarter And Full Year 2017 Financial Results On Monday, February 26, 2018

Exelixis, Inc. (NASDAQ: EXEL) announced today that its fourth quarter and full year 2017 financial results will be released on Monday, February 26, 2018 after the markets close.

Exelixis Announces Updated Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab With Or Without Ipilimumab In Refractory Genitourinary (GU) Tumors

Exelixis Announces Updated Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab With Or Without Ipilimumab In Refractory Genitourinary (GU) Tumors

Exelixis, Inc. (NASDAQ:EXEL) today announced updated data from expansion cohorts in a phase 1 trial of cabozantinib in combination with either nivolumab or nivolumab plus ipilimumab in patients with refractory...

Exelixis To Present At The Leerink Partners Global Healthcare Conference On February 14

Exelixis To Present At The Leerink Partners Global Healthcare Conference On February 14

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Jim Cramer highlights Anthem, A.O. Smith, Tableau Software, Electro Scientific Industries, CRISPR Therapeutics.

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Jim Cramer says this is the scary process that gets us back to where we can maintain a real, not parabolic, advance.

Exelixis Larger Than S&P 500 Component Federal Realty Investment Trust

Exelixis Larger Than S&P 500 Component Federal Realty Investment Trust

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Exelixis Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Federal Realty Investment Trust , according to The Online Investor. Market capitalization is an important data point for investors to keep an eye on, for various reasons.

Exelixis Announces Presentation Of Updated Phase 1b Results For The Combination Of Cobimetinib And Atezolizumab In Metastatic Colorectal Cancer At The 2018 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

Exelixis Announces Presentation Of Updated Phase 1b Results For The Combination Of Cobimetinib And Atezolizumab In Metastatic Colorectal Cancer At The 2018 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

Exelixis, Inc. (NASDAQ:EXEL) today announced the presentation of updated results from the Genentech-sponsored phase 1b clinical trial of cobimetinib (COTELLIC ®), an Exelixis-discovered MEK inhibitor, in...

CELESTIAL Trial Design Fact Sheet

CELESTIAL Trial Design Fact Sheet

Exelixis, Inc. (NASDAQ:EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced detailed results of the pivotal phase 3 CELESTIAL trial in patients with previously treated advanced hepatocellular carcinoma (HCC),...

Exelixis To Co-Host Financial Community Briefing To Discuss Data Presented At The 2018 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

Exelixis To Co-Host Financial Community Briefing To Discuss Data Presented At The 2018 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

Exelixis, Inc. (NASDAQ: EXEL) today announced that the company, along with its partner Ipsen, will host a live briefing event for the financial community to discuss data presented at the 2018 American Society of Clinical...

Exelixis And StemSynergy Enter Into Exclusive Licensing Agreement For The Discovery And Development Of Novel Anticancer Therapies

Exelixis And StemSynergy Enter Into Exclusive Licensing Agreement For The Discovery And Development Of Novel Anticancer Therapies

Exelixis, Inc. (NASDAQ: EXEL) today announced that it has entered into an exclusive collaboration and license agreement with StemSynergy Therapeutics, Inc.

TheStreet Quant Rating: C+ (Hold)